# Myosteatosis: A Distinct, Early and Targetable Novel Biomarker of Cancer Prognosis

## TL;DR

Myosteatosis, a condition where fat builds up in muscles, is an early and treatable predictor of cancer outcomes that could improve patient survival and quality of life.

## Contribution

This paper identifies myosteatosis as a novel, early biomarker of cancer prognosis that is distinct from sarcopenia and cachexia.

## Key findings

- Myosteatosis is highly prevalent in cancer patients and is independently linked to mortality and treatment toxicity.
- It appears early in muscle deterioration, before cachexia develops, making it a potential target for intervention.
- Unlike sarcopenia, myosteatosis reflects impaired muscle quality and metabolic dysfunction.

## Abstract

Myosteatosis is a condition where fat builds up inside and around muscles. Although not yet widely recognized, growing evidence shows it can strongly affect how people with cancer respond to treatment and how well they do over time. This paper reviews existing research to explain what myosteatosis is, how common it is, why it develops, and how it influences cancer treatment side effects, the chance of cancer coming back, and overall survival. Importantly, the review shows that myosteatosis may appear early, before obvious weight or muscle loss, making it a promising early warning sign of poor outcomes. The review also reveals major gaps in current knowledge. To move the field forward, coordinated research is needed to better understand the biology of myosteatosis, agree on how it should be measured, and develop targeted strategies to prevent or treat it. Addressing myosteatosis could help patients tolerate cancer treatments better, live longer, and maintain a better quality of life throughout their cancer journey.

Background: Myosteatosis—fat infiltration within skeletal muscle—is emerging as a critical yet underappreciated determinant of cancer outcomes. Although historically overshadowed by sarcopenia and cachexia, myosteatosis is now recognized as a distinct and early muscle phenotype that carries significant prognostic implications across multiple tumor types. Despite its relevance, foundational gaps remain in our understanding of its mechanisms, clinical significance, and therapeutic potential. The goal of this manuscript is to review the current literature to identify the unique characteristics, prevalence, biological and other etiological mechanisms of myosteatosis and its role as an early biomarker in cancer treatment, recurrence, and prognosis. Methods: A review of the evidence from epidemiological, laboratory and other observational studies with regard to the definition of the biomarker, its biological mechanism, its prevalence in cancer patient populations and the gaps in the research was conducted. Results: Retrospective studies utilizing CT imaging reveal that myosteatosis is highly prevalent in cancer populations and independently associated with mortality, treatment toxicity, postoperative complications, functional decline, and survivorship outcomes. Unlike sarcopenia, which primarily reflects loss of muscle mass, myosteatosis reflects impaired muscle quality, metabolic dysfunction, and lipid derangements. Importantly, it appears early in the trajectory of muscle deterioration—well before irreversible cachexia develops—making it a strategic point for intervention. Conclusions: Despite strong associations with clinical outcomes, the biological underpinnings, clinical applications, and modifiability of myosteatosis remain poorly defined. A coordinated research agenda focused on mechanistic discovery, biomarker standardization, and targeted interventions is essential to improving survival, treatment tolerance, and quality of life for patients across the cancer continuum.